CIBINETIDE

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C51H84N16O21
Molecular Weight	1257.3093
Optical Activity	UNSPECIFIED
Defined Stereocenters	11 / 11
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O

InChI

InChIKey=WZTIQQBMSJTRBR-WYKNNRPVSA-N

InChI=1S/C51H84N16O21/c1-22(2)17-30(47(84)65-32(19-36(53)71)48(85)66-33(20-68)49(86)67-34(21-69)50(87)88)63-40(77)24(5)57-41(78)25(7-6-16-56-51(54)55)59-43(80)29(11-15-39(75)76)62-46(83)31(18-23(3)4)64-45(82)27(8-12-35(52)70)60-44(81)28(10-14-38(73)74)61-42(79)26-9-13-37(72)58-26/h22-34,68-69H,6-21H2,1-5H3,(H2,52,70)(H2,53,71)(H,57,78)(H,58,72)(H,59,80)(H,60,81)(H,61,79)(H,62,83)(H,63,77)(H,64,82)(H,65,84)(H,66,85)(H,67,86)(H,73,74)(H,75,76)(H,87,88)(H4,54,55,56)/t24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C51H84N16O21
Molecular Weight	1257.3093
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	11 / 11
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26431906 | https://www.ncbi.nlm.nih.gov/pubmed/28475703 | https://www.ncbi.nlm.nih.gov/pubmed/30876881 | https://www.ncbi.nlm.nih.gov/pubmed/29223734

Cibinetide (ARA 290; helix B surface peptide) is a novel potent and selective peptide agonist of innate repair receptor (IRR) with anti-inflammatory and tissue-protective activities. IRR activation promotes tissue protection and repair in a wide variety of preclinical models, including diabetic wound healing, diabetic neuropathy, and ischemic retinopathy. In a mouse model of diabetic small nerve fiber loss, daily administration of Cibinetide reversed neuronal dystrophy. Cibinetide administration significantly improved re-epithelization, angiogenesis, and wound healing strength in a mouse model of diabetic wounds. In clinical studies, Cibinetide administration has shown significantly increased small nerve fiber abundance, reduced neuropathic symptoms and promoted nerve fiber repair in patients with sarcoidosis or diabetes-related nerve fiber loss.

Originator

Approval Year

PubMed

Title	Date	PubMed
The vasoreparative potential of endothelial colony-forming cells in the ischemic retina is enhanced by cibinetide, a non-hematopoietic erythropoietin mimetic.	2019-05	30876881

Patents

Sample Use Guides

In Vivo Use Guide

1, 4, or 8 mg cibinetide or placebo daily for 28 days

Route of Administration: Other

Substance Class	Chemical Created by `admin` on `Mon Mar 31 20:49:48 GMT 2025` Edited by `admin` on `Mon Mar 31 20:49:48 GMT 2025`
Record UNII	9W5677JKDA
Record Status	`FAILED`
Record Version

Download

Name

Type

Language

CIBINETIDE

Official Name

English

cibinetide [INN]

Preferred Name

English

L-SERINE, 5-OXO-L-PROLYL-L-.ALPHA.-GLUTAMYL-L-GLUTAMINYL-L-LEUCYL-L-.ALPHA.-GLUTAMYL-L-ARGINYL-L-ALANYL-L-LEUCYL-L-ASPARAGINYL-L-SERYL-

Systematic Name

English

PYR-GLU-GLN-LEU-GLU-ARG-ALA-LEU-ASN-SER-SER-OH

Common Name

English

ARA-290

Code

English

PH-BSP

Common Name

English

PHBSP

Common Name

English

L-PYR-L-GLU-L-GLN-L-LEU-L-GLU-L-ARG-L-ALA-L-LEU-L-ASN-L-SER-L-SER

Common Name

English

ARA290

Code

English

Cibinetide [WHO-DD]

Common Name

English

ARA 290

Code

English

L-PYROGLUTAMYL-L-GLUTAMYL-L-GLUTAMINYL-L-IEUCYL-L-GLUTAMYL-L-ARGINYL-L-ALANYL-L-LEUCYL-L-ASPARAGINYL-L-SERYL-L-SERINE

Systematic Name

English

CIBINETIDE [USAN]

Common Name

English

L-PYROGLUTAMYL-L-GLUTAMYL-L-GLUTAMINYL-L-LEUCYL-L-GLUTAMYL-L-ARGINYL-L-ALANYL-L-LEUCYL-L-ASPARAGINYL-L-SERYL-L-SERINE

Systematic Name

English

PGLU-GLU-GLN-LEU-GLU-ARG-ALA-LEU-ASN-SER-SER

Common Name

English

Classification Tree Code System Code

EU-Orphan Drug

EU/3/16/1721